Skip to main navigation
Skip to main content

Utility Nav Header

  • Contact

Main navigation

  • About
    • Scientific Advisory Board
    • Corporate Responsibility
      • Corporate Governance
      • Corporate Giving
  • Our Science
    • Our Approach
    • Pipeline
      • Pipeline
      • Repotrectinib
      • Elzovantinib (TPX-0022)
      • TPX-0046
      • TPX-0131
      • TPX-4589
    • Publications & Presentations
  • Clinical Trials
    • Company Trials
    • Compassionate Use
    • Investigator Sponsored Research
  • Careers
    • Diversity & Inclusion
    • Opportunities

Sitemap

Main navigation

  • About
    • Scientific Advisory Board
    • Corporate Responsibility
      • Corporate Governance
      • Corporate Giving
  • Our Science
    • Our Approach
    • Pipeline
      • Pipeline
      • Repotrectinib
      • Elzovantinib (TPX-0022)
      • TPX-0046
      • TPX-0131
      • TPX-4589
    • Publications & Presentations
  • Clinical Trials
    • Company Trials
    • Compassionate Use
    • Investigator Sponsored Research
  • Careers
    • Diversity & Inclusion
    • Opportunities

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb

BMS
Copyright © 2023 Turning Point Therapeutics, Inc. | All Rights Reserved | Sitemap | Terms of Use | Privacy Policy Statement